NDAORALSOLUTION
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
BRYNOVIN (sitagliptin hydrochloride oral) by R-Pharm US is dipeptidyl peptidase 4 inhibitors [moa]. Approved for type 2 diabetes mellitus. First approved in 2025.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRYNOVIN is a DPP-4 inhibitor oral solution containing sitagliptin hydrochloride, approved January 2025 for type 2 diabetes mellitus. It works by inhibiting dipeptidyl peptidase-4, an enzyme that degrades incretin hormones, thereby enhancing glucose-dependent insulin secretion and reducing hyperglycemia. This is a small-molecule oral therapeutic in a mature but still-relevant diabetes class.
Growth14.2 years to LOE
BRYNOVIN enters a competitive but established oral diabetes market as a growth-stage product; early-stage brand teams will focus on market penetration and differentiation against entrenched competitors.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications (1)
Career Relevance
BRYNOVIN entry into a mature, competitive diabetes market with low growth signals means career opportunities will focus on brand defense, formulary negotiation, and sales execution rather than expansion. Roles will emphasize tactical commercial skills and physician relationship management in a price-sensitive, GLP-1-dominated market.
Worked on BRYNOVIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.